格隆汇5月8日丨来凯医药-B(02105.HK)公告,于2025年5月8日,根据2024年股份奖励计划向承授人(包括三名执行董事)授出合共1146万份受限制股份单位(相当于合共11,460,000股股份)。向包括吕向阳、谢玲及顾祥巨在内的三名执行董事授出受限制股份单位须待独立股东在股东周年大会上批准后,方可作实。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.